U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
(Mark One)
[X] | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2007
or
[_] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 |
For the transition period from _____ to _____
Commission file number 333-137545
Lab 123, Inc.
(Exact Name of Small Business Issuer as Specified in its Charter)
Delaware | 45-0542515 |
(State or other jurisdiction of | (I.R.S. Employer |
incorporation or organization) | Identification No.) |
100 Field Drive, Suite 240, Lake Forest, Illinois 60045
(Address of principal executive offices)
847-234-8111
(Issuer's Telephone Number)
Not Applicable
(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)
Check whether the issuer: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.) Yes [ ] No [X]
The Company had 6,175,000 shares of common stock, $0.001 par value, issued and outstanding as of January 17, 2008.
TRANSITIONAL SMALL BUSINESS DISCLOSURE FORMAT (CHECK ONE):
Yes [ ] No [X]
INDEX
PART I - FINANCIAL INFORMATION
Item 1
Page | |
Condensed Balance Sheet as of September 30, 2007 (unaudited) | 3 |
Condensed Statements of Operations for the three and nine months ended September 30, 2007, for the period August 25, 2006 (date of inception) to September 30, 2006 and for the period August 25, 2006 (date of inception) to September 30, 2007 (unaudited) | 4 |
Condensed Statement of Changes in Stockholders’ Equity for the nine months ended September 30, 2007 (unaudited) | 5 |
Condensed Statements of Cash Flows for the nine months ended September 30, 2007, for the period August 25, 2006 (date of inception) to September 30, 2006 and for the period August 25,2006 (date of inception) to September 30, 2007 (unaudited) | 6 |
Notes to Condensed Financial Statements as of September 30, 2007 (unaudited) | 7 |
Item 2. Management's Discussion and Analysis or Plan of Operations | 14 |
Item 3. Controls and Procedures | 19 |
PART II - OTHER INFORMATION | |
Item 1. Legal Proceedings | 20 |
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 20 |
Item 3. Defaults Upon Senior Securities | 20 |
Item 4. Submission of Matters to a Vote of Security Holders | 20 |
Item 5. Other Information | 20 |
Item 6. Exhibits | 21 |
Signatures | 22 |
Certifications |
2
PART I. Financial Information
Item 1. Financial Statements
Lab123, Inc. | |
(A Development Stage Company) | |
Condensed Balance Sheet | |
September 30, 2007 | |
(Unaudited) |
ASSETS | ||||
Current Assets | ||||
Cash | 45,672 | |||
Accounts receivable, net of allowance for doubtful accounts $17,500 | 166,677 | |||
Inventory | 86,198 | |||
Inventory deposits with Biosafe - related party | 287,844 | |||
Total Current Assets | 586,391 | |||
Fixed assets, net of accumulated depreciation $496 | 1,772 | |||
License agreement, net of accumulated amortization $100,000 | 900,000 | |||
TOTAL ASSETS | 1,488,163 | |||
LIABILITIES & STOCKHOLDERS' EQUITY | ||||
Current Liabilities | ||||
Accounts payable | 102,090 | |||
Accrued expenses | 6,699 | |||
Due to BioSafe - related party | 16,401 | |||
Total Current Liabilities | 125,190 | |||
Commitments and Contingencies | ||||
Stockholders' Equity | ||||
Series A Convertible Preferred Stock - .001 par value; 6,000,000 authorized; | ||||
3,774,000 issued and outstanding | 3,774 | |||
Common Stock - .001 par value; 21,000,000 authorized; 6,175,000 issued and outstanding | 6,175 | |||
Additional paid-in capital | 3,187,632 | |||
Deficiency accumulated during the development stage | (1,834,608 | ) | ||
Total Stockholders' Equity | 1,362,973 | |||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 1,488,163 |
See notes to condensed financial statements. |
3
Lab123, Inc. | ||||
(A Development Stage Company) | ||||
Condensed Statements of Operations | ||||
(Unaudited) |
For the Three Months Ended September 30, 2007 | For the Period August 25, 2006 (Date of Inception) to September 30, 2006 | For the Nine Months ended September 30, 2007 | For the Period August 25, 2006 (Date of Inception) to September 30, 2007 | ||||||||||||||
REVENUE, net of discounts | 200,296 | 5,916 | 331,570 | 587,427 | |||||||||||||
COST OF GOODS SOLD: | |||||||||||||||||
Cost of goods sold - related party | 85,175 | 3,609 | 138,119 | 270,173 | |||||||||||||
Amortization of license - related party | 25,000 | 75,000 | 100,000 | ||||||||||||||
Total Costs of Goods Sold | 110,175 | 3,609 | 213,119 | 370,173 | |||||||||||||
GROSS MARGIN | 90,121 | 2,307 | 118,451 | 217,254 | |||||||||||||
OPERATING EXPENSES: | |||||||||||||||||
Compensation (includes stock based compensation of | 43,253 | 136,081 | 167,043 | 245,470 | |||||||||||||
$108,000 for the period 8/25/06 to 9/30/06) | |||||||||||||||||
Professional fees | 23,414 | - | 139,867 | 192,182 | |||||||||||||
Administrative fee - related party | 45,000 | 12,372 | 135,000 | 192,372 | |||||||||||||
Web-site lease - related party | 15,000 | - | 35,095 | 35,095 | |||||||||||||
Other administrative costs | 7,685 | 3,311 | 37,525 | 55,380 | |||||||||||||
Bad debt expense | 3,558 | - | 3,558 | 18,558 | |||||||||||||
Depreciation | 180 | - | 540 | 676 | |||||||||||||
Total Operating Expenses | 138,090 | 151,764 | 518,628 | 739,733 | |||||||||||||
Loss Before Provision for Income Taxes | 47,969 | (149,457 | ) | (400,177 | ) | (522,479 | ) | ||||||||||
NET LOSS | (47,969 | ) | (149,457 | ) | (400,177 | ) | (522,479 | ) | |||||||||
Deemed dividend on preferred stock | - | (524,500 | ) | (787,629 | ) | (1,312,129 | ) | ||||||||||
Net Loss applicable to common stockholders | (47,969 | ) | (673,957 | ) | (1,187,806 | ) | (1,834,608 | ) | |||||||||
Net Loss per Common Share | |||||||||||||||||
(Basic and Diluted) | (0.01 | ) | (0.03 | ) | (0.06 | ) | |||||||||||
Net Loss applicable to common stockholders | |||||||||||||||||
per Common Share (Basic and Diluted) | (0.01 | ) | (0.13 | ) | (0.19 | ) | |||||||||||
Weighted average common shares outstanding | |||||||||||||||||
(Basic and Diluted) | 6,175,000 | 5,240,278 | 6,175,000 |
See notes to condensed financial statements. |
4
Lab123, Inc.
(A Development Stage Company)
Statement of Changes in Stockholder's Equity
For the Nine Months ended September 30 2007
(Unaudited)
Deficiency | ||||||||||||||||||||||||||||
Accumulated | ||||||||||||||||||||||||||||
Additional | During the | Total | ||||||||||||||||||||||||||
Preferred Stock | Common Stock | Paid - in | Development | Stockholders' | ||||||||||||||||||||||||
Shares | Amount | Share | Amount | Capital | Stage | Equity | ||||||||||||||||||||||
Balance at January 1, 2007 | 3,774,000 | $ | 3,774 | 6,175,000 | $ | 6,175 | $ | 2,400,003 | $ | (646,802 | ) | $ | 1,763,150 | |||||||||||||||
Deemed Dividend | 787,629 | (787,629 | ) | |||||||||||||||||||||||||
Net Loss | (400,177 | ) | (400,177 | ) | ||||||||||||||||||||||||
Balance at September 30, 2007 | 3,774,000 | 3,774 | 6,175,000 | 6,175 | 3,187,632 | (1,834,608 | ) | 1,362,973 |
See notes to condensed financial statements |
5
Lab123, Inc.
(A Development Stage Company)
Condensed Statements of Cash Flows
(Unaudited)
For the Nine Months ended September 30, 2007 | For the Period August 25, 2006 (Date of Inception) to September 30, 2006 | For the Period August 25, 2006 (Date of Inception) to September 30, 2007 | ||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||
Net Loss | (400,177 | ) | (149,457 | ) | (522,479 | ) | ||||||
Adjustments to reconcile net loss to net cash used by operating activities: | ||||||||||||
Depreciation | 540 | - | 676 | |||||||||
Amortization of license agreement - related party | 75,000 | - | 100,000 | |||||||||
Stock Based Compensation | - | 117,000 | - | |||||||||
Reserve for inventory | (56,145 | ) | - | 20,261 | ||||||||
Bad Debt | 3,558 | - | 18,558 | |||||||||
Changes in operating assets and liabilities : | ||||||||||||
Accounts receivable | 19,373 | (5,916 | ) | (185,235 | ) | |||||||
Inventory | 3,434 | (118,994 | ) | (106,459 | ) | |||||||
Inventory deposits Biosafe - related party | 12,156 | (287,844 | ) | |||||||||
Other prepaid assets | - | (15,000 | ) | - | ||||||||
Accounts payable | (942 | ) | 104,514 | 102,090 | ||||||||
Accrued expenses | 588 | 20,276 | 6,699 | |||||||||
Due to Biosafe - related party | (20,970 | ) | - | 16,401 | ||||||||
Net cash used in operating activities | (363,585 | ) | (47,577 | ) | (837,332 | ) | ||||||
CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||
Purchase of license from Biosafe - related party | - | (1,000,000 | ) | (1,000,000 | ) | |||||||
Purchase of equipment | - | - | (2,448 | ) | ||||||||
Net cash used investing activities | - | (1,000,000 | ) | (1,002,448 | ) | |||||||
CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||
Net proceeds from sale of Series A Convertible Preferred Stock | - | 1,885,452 | 1,885,452 | |||||||||
Net cash provided by financing activities | - | 1,885,452 | 1,885,452 | |||||||||
NET (DECREASE) INCREASE IN CASH | (363,585 | ) | 837,875 | 45,672 | ||||||||
CASH AT BEGINNING OF PERIOD | 409,257 | - | - | |||||||||
CASH AT END OF PERIOD | 45,672 | 837,875 | 45,672 | |||||||||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||||||
Cash paid for Interest | - | - | - | |||||||||
Cash paid for Income Taxes | - | - | - |
See notes to condensed financial statements. |
6
Lab123, Inc.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 - Organization, Business and Operations
Lab123, Inc. (a development stage company) (“Lab123” or the “Company”) is currently a development stage company under the provisions of Statement of Financial Accounting Standards (“SFAS”) No. 7, Development Stage Enterprises and was incorporated in Delaware on August 25, 2006. Lab123 is a marketing, distributing and manufacturing company whose objective is to license, broker or acquire retail medical diagnostic products and services to sell into retail drug stores and chains in the United States and to internet drug retailers. The Company has commenced operations and will continue to report as a development stage company until significant revenues are generated. The corporate office is located in Lake Forest, Illinois.
NOTE 2 – Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying unaudited condensed interim financial statements include the accounts of Lab123. These unaudited, condensed interim financial statements have been prepared in accordance with accounting principles generally accepting in the United States of America for interim financial information and with the instructions to Form 10-QSB. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America ("GAAP") for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included.
The operating results for the three and nine month periods ended September 30, 2007 are not necessarily indicative of the results that may be expected for the year ending December 31, 2007 or for any other interim period. These financial statements should be read in conjunction with the financial statements and footnotes thereto included in the Company's Annual Report on Form 10-KSB, filed on June 20, 2007. The accounting policies used in preparing these unaudited condensed interim financial statements are consistent with those described in the December 31, 2006 audited financial statements except for the adoption of Financial Accounting Standards Board ("FASB") Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of FASB Statement No. 109"("FIN 48"), which is discussed in Note 2.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.
Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. The most significant estimates, among other things, are used in accounting for allowances for bad debts, inventory valuation and obsolescence, deferred income taxes, expected realizable values for long-lived assets (primarily intangible assets), contingencies, revenue recognition as well as the recording and presentation of our convertible preferred stock and related warrants. Estimates and assumptions are periodically reviewed and the effects of any material revisions are reflected in the consolidated financial statements in the period that they are determined to be necessary. Actual results could differ from those estimates and assumptions
Development Stage Company
The Company has generated nominal revenues to date; accordingly, the Company is considered a development stage enterprise as defined in Financial Accounting Standards Board No. 7, "Accounting and Reporting for Development Stage Companies." The Company is subject to a number of risks similar to those of other companies in an early stage of development.
7
Loss Per Common Share
Basic (loss) per share have been calculated based upon the weighted average number of common shares outstanding. The Series A Preferred and Warrants have been excluded as common stock equivalents in the diluted earnings per share because their effect would be anti-dilutive. The aggregate number of potential common stock equivalents outstanding as of September 30, 2007 and 2006 not included in basic and diluted net loss per share is as follows:
September 30, 2007 | September 30, 2006 | |||||||
Series A Preferred | 6,250,000 | 3,774,000 | ||||||
Warrants | 3,774,000 | 3,774,000 | ||||||
Total | 10,024,000 | 7,548,000 |
Revenue Recognition
Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed or determinable, the collectibility is reasonable assured, and the delivery and acceptance of the product has occurred. Management exercises judgment in evaluating these factors in light of the terms and conditions of its customer contracts and other existing facts and circumstances to determine the appropriate revenue recognition. Due to limited commercial sales history, the Company’s ability to evaluate the collectibility of customer accounts requires significant judgment. Sales discounts and allowances are recorded at the time product sales are recognized and are offset against sales revenue. Consignment sales or “pay-on-scan” sales are recorded as revenue when the sale at the retail store level has occurred. If a sale occurs that has a right-of-return, a reserve for returns will be created using Company and industry experience as to rates of return. Service revenue is recognized in the period in which the service was performed. For the nine months ended September 30, 2007, the Company issued an aggregate of approximately $24,000 of discounts related to the early payment of receivables and sales discounts.
Accounting for Preferred Stock and Related Warrants
The Company accounted for the Series A Preferred in accordance with Emerging Issues Task Force ("EITF") No. 98-5 "Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios" ("EITF 98-5"), EITF No. 00-27 "Application of Issue No. 98-5 to Certain Convertible Instruments". The warrants and conversion option will be accounted for under EITF No. 00-19 "Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock" ("EITF 00-19"). The warrants and conversion option were not deemed to be a derivative liability in accordance with SFAS No. 133 (par 1la) as the contracts were indexed to the Company's own stock and qualified as equity in the balance sheet.
Stock Based Compensation
The Company accounts for its share based payment awards in accordance with SFAS No. 123R "Share Based Payment". This statement is a revision of SFAS Statement No. 123, and supersedes APB Opinion No. 25, and its related implementation guidance. SFAS 123R addresses all forms of share based payment ("SBP") awards including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. Under SFAS 123R, SBP awards will result in a charge to operations that will be measured at fair value on the awards grant date, based on the estimated number of awards expected to vest over the service period.
The Company did not incur a charge for stock based compensation for the three and nine months ended September 30, 2007.
Recently Adopted Pronouncements
The Company adopted Financial Accounting Standards Board's Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109" ("FIN 48"), effective January 1, 2007. FIN 48 clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. FIN 48 is effective for fiscal years beginning after December 15, 2006, and is to be applied to all open tax years as of the date of effectiveness. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There were no unrecognized tax benefits as of January 1, 2007.
8
The Company has identified its federal tax return and its state tax returns in Illinois as "major" tax jurisdictions, as defined. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The evaluation was performed for the 2006 tax year, which will be the only period subject to examination, since the Company was formed on August 25, 2006. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. In addition, the Company did not record a cumulative effect adjustment related to the adoption of FIN 48.
The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income tax expense. No interest or penalties on income taxes have been recorded during the three months ended September 30, 2007. The Company does not expect its unrecognized tax benefit position to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position. The adoption of the provisions of FIN 48 did not have a material impact on the Company’s financial position, results of operations and cash flows.
Recent Accounting Pronouncements
In September 2006, the FASB issued SFAS No. 157, "Accounting for Fair Value Measurements." SFAS No. 157 defines fair value, and establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements. SFAS No. 157 is effective for financial statements issued subsequent to November 15, 2007. The Company does not expect the new standard to have any material impact on the financial position, results of operations and cash flows.
In December 2006, the FASB issued FASB Staff Position (“FSP”) EITF 00-19-2 “Accounting for Registration Payment Arrangements” (“FSP EITF 00-19-2”) which specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement should be separately recognized and measured in accordance with SFAS No. 5, “Accounting for Contingencies.” Adoption of FSP EITF 00-19-02 is required for fiscal years beginning after December 15, 2006. The adoption of FSP EITF 00-19-02 did not have a material impact on the Company’s condensed consolidated financial position, results of operations or cash flows.
In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS 159"). SFAS 159 provides companies with an option to report selected financial assets and liabilities at fair value. The objective of SFAS 159 is to reduce both complexity in accounting for financial instruments and the volatility in earnings caused by measuring related assets and liabilities differently. Generally accepted accounting principles have required different measurement attributes for different assets and liabilities that can create artificial volatility in earnings. The FASB has indicated it believes that SFAS 159 helps to mitigate this type of accounting-induced volatility by enabling companies to report related assets and liabilities at fair value, which would likely reduce the need for companies to comply with detailed rules for hedge accounting. SFAS 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 does not eliminate disclosure requirements included in other accounting standards, including requirements for disclosures about fair value measurements included in SFAS 157 and SFAS No. 107, "Disclosures about Fair Value of Financial Instruments." SFAS 159 is effective for the Company as of the beginning of an entity’s first fiscal year that begins after November 15, 2007. The adoption of this pronouncement is not expected to have an impact on the Company's financial position, results of operations or cash flows.
NOTE 3 – Liquidity and Financial Condition
These condensed financial statements have been prepared in accordance with generally accepted accounting principles applicable to a going concern, which implies the Company will continue to meets its obligations and continue its operations for the next fiscal year. Realization values may be substantially different from carrying values as shown and these condensed interim financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has accumulated net losses of $522,479 since inception and may not have sufficient working capital to sustain its operations.. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.
9
As described more fully in Note 4, on September 6, 2006 the Company entered into a convertible preferred stock purchase agreement with Barron Partners for a total of $2,000,000. These proceeds have been used primarily to fund the Company’s working capital needs and partially fund the license purchased from BioSafe for certain retail medical diagnostic products to sell into the retail drug stores and chains the United States and internet drug retailers.
The continuation of the Company as a going concern is dependent upon the continued financial support from its stockholders, the ability of the Company to obtain additional necessary equity financing to continue operations, and the attainment of profitable operations. Management is continuously exploring opportunities to increase revenues in new business areas. Management has plans in place to address this concern and expects that the Company will be able to obtain additional funds by equity financing and/or related party advances. However, there can be no assurance that the Company can continue to raise additional funds on terms that are acceptable or available at all. The inability to raise necessary funds can have a material adverse effect on the Company's financial position, results of operations and cash flows. If the Company is not successful in obtaining the necessary financing to implement its business plan it may be necessary for the Company to curtail its operations.
The Company is currently in negotiations with Barron concerning a repurchase by the Company of the securities sold to Barron (see Notes 4 and 7) and is attempting to secure the necessary financing for this transaction. However, there can be no assurance that such negotiations will result in the parties entering into and consummating any repurchase or other transaction. As of September 30, 2007 the Company has determined that the Series A Preferred is equity as the Company has not entered into a definitive agreement with Barron, there have been no amendments to the purchase agreement or any other documents, instruments or agreements that would classify the Series A Preferred as redeemable and the Company is not legally obligated to Barron to provide $2,000,000 for the repurchase of the Series A Preferred.
NOTE 4 - Barron Private Placement
On September 6, 2006 the Company entered into a convertible preferred stock purchase agreement (“Purchase Agreement”) with Barron Partners (“Barron”) to issue 3,774,000 shares of Series A Convertible Preferred Stock (“Series A Preferred”) at $0.53 per share, for a total of $2,000,000. One share of Series A Preferred is initially convertible into one share of Common Stock at any time, except that at no time may Barron own any more than 4.9% of the Company’s issued and outstanding common stock. In addition, Barron received warrants to purchase 3,774,000 shares of common stock (“Warrants”). The Warrants entitle the holder to purchase from the Company an equal number of common stock at an exercise price per share of $0.80 for 1,887,000 shares and $1.10 for the remaining 1,887,000 shares. The warrants are exercisable immediately and shall expire five years from the purchase date; the warrants carry a cashless exercise provision. Barron was required to be reimbursed $85,000 to cover its due diligence and transaction costs and as of September 30, 2007 the balance is included as part of accounts payable.
Pursuant to the terms of the Purchase Agreement, from September 6, 2006, the purchase date, until the expiration of 48 months after the Closing Date or until Barron owns less than 5% of their Series A Preferred, whichever occurs first, if the Company closes on the sale of a note or notes, shares of common stock, or shares of any class of Preferred Stock at a price per share of common stock, or with a conversion right to acquire common stock at a price per share of common stock, that is less than the conversion value the Company shall make a post-purchase adjustment in the conversion value so that the conversion value is reduced to price per share of common stock or conversion price of the securities sold.
Conversion price adjustment based on 2006 and 2007 earnings per share:
In the event the Company earns between $0.0306 and $0.0187 (40% Decline) per share (where such earnings in this computation shall always be defined as earnings on a pre tax fully diluted basis for the period from August 25, 2006 (Date of Inception) to December 31, 2006 from continuing operations before any non-recurring items), the then current conversion value at the time the 2006 Audited Financials are filed with the SEC shall be decreased proportionally by 0% if the earnings are $0.0306 per share or greater and by 40% if the earnings are $0.0187 per share or less.
10
During the second quarter ended June 30, 2007, the Company determined under the terms of the agreement that earnings per share for the period from August 25, 2006 (Date of Inception) to December 31, 2006 were less than the $0.0187 and, accordingly, reduced the conversion price of the Series A Preferred by 40% from $0.53 to $0.32. The Company recognized an additional deemed dividend for the conversion price reduction of approximately $788,000 during the second quarter ended June 30, 2007.
In the event the Company earns between $0.19 and $0.1446 (25% Decline) per share (where such earnings in the computation shall always be defined as earnings on a pre tax fully diluted basis for the year ended December 31, 2007 from continuing operations before any non-recurring items), the then current conversion value at the time the 2007 Audited Financials are filed with the SEC shall be decreased proportionally by 0% if the earnings are $0.19 per share or greater and by 25% if the earnings are $0.1446 per share or less.
The Purchase Agreement also contains certain covenants including:
· | For five years after Closing the Company shall not to enter into any new borrowings of more than twice as much as the sum of the EBITDA from recurring operations over the past four quarters without Barron’s consent. |
· | A majority of the Board of Directors must include qualified independent members. |
· | In any future stock issuance, Barron has the right to purchase issued shares sufficient to prevent dilution. |
The Series A Preferred will be accounted for in accordance with Emerging Issues Task Force (“EITF”) No. 98-5 “Accounting for Convertible Securities with Beneficial Conversion Features or Contingently Adjustable Conversion Ratios” (“EITF 98-5”), EITF No. 00-27 “Application of Issue No. 98-5 to Certain Convertible Instruments”.
The Warrants and conversion option will be accounted for under EITF No. 00-19 “Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock” (“EITF 00-19”). The Warrants and conversion option were not deemed to be a derivative liability in accordance with SFAS No. 133 (par 11a) as the contracts did not require net cash settlements, were indexed to the Company’s own stock and qualified as equity in the balance sheet.
On September 6, 2006 The Company entered into a registration rights agreement with Barron whereby the Company is required to file a registration statement with the SEC, to register the resale of the shares of common stock that the Company will issue upon conversion of the Series A Preferred and exercise of Warrants issued to Barron.
The Company was required to use its best efforts to cause the registration statement to be declared effective within 120 days of the closing date and obtained an effective registration statement on January 10, 2007.
The Company accounts for potential registration rights liquidated damage obligations in accordance with FSP EITF 00-19-2 “Accounting for Registration Payment Arrangements.” The Company has adopted this pronouncement during the quarter ended March 31, 2007. The adoption of FSP EITF 00-19-02 did not have a material impact on the Company’s condensed consolidated financial position, results of operations or cash flows.
The Company is required to provide for a net share settlement of the liquidated damages provision, there are sufficient authorized and unissued shares for the maximum amount issuable and under no circumstances does the agreement provide for an alternative net cash settlement of the liquidated damages.
The Company is currently in negotiations with Barron concerning a repurchase by the Company of the securities sold to Barron (see Notes 4 and 7) and is attempting to secure the necessary financing for this transaction. However, there can be no assurance that such negotiations will result in the parties entering into and consummating any repurchase or other transaction. As of September 30, 2007 the Company has determined that the Series A Preferred is equity as the Company has not entered into a definitive agreement with Barron, there have been no amendments to the purchase agreement or any other documents, instruments or agreements that would classify the Series A Preferred as redeemable and the Company is not legally obligated to Barron to provide $2,000,000 for the repurchase of the Series A Preferred.
11
Biosafe and its affiliates is an affiliated company whose Chairman is the former Chairman of the Company. BioSafe is a shareholder and owns approximately 98% of the Company’s outstanding common stock and is the licensor of the Company’s license agreement. Biosafe’s products specialize in the use of micro-sample blood transportation devices and unique, scientific procedures for the clinical testing of these micro-blood samples. From time to time the Company may obtain terms that are beneficial to the Company that the Company may not normally obtain if the Company would seek the same terms from an outside vendor.
BioSafe provides office space, administrative and financial services for a monthly fee of approximately $15,000, for the three and nine months ended September 30, 2007 the Company incurred a charge of $45,000 and $135,000 respectively.
As of September 30, 2007, the Company has a deposit outstanding to BioSafe of $300,444, for the purchase of approximately $600,000 of inventory. The Company plans the receipt of this inventory by the end of 2007 or as required by the Company to meet customer and inventory needs.
The Company entered into a website lease agreement with a company whose owner is also the son of the former Chairman of the Company. The lease calls for monthly lease payments of $5,000 with an option to purchase the website for an incremental $50,000 at any time before the license expires at December 31, 2007.
NOTE 6- Inventory, Net
Inventory consisted of $86,198 primarily of finished goods on consignment.
NOTE 7 – Legal Proceedings
On December 10, 2007, Barron filed a Complaint in the United States District Court for the Sothern District of New York against the Company, certain present and former directors and consultants to the Company and certain other persons, including Biosafe Laboratories, Inc. and Biosafe Medical Technologies, Inc. to recover unquantified damages against the defendants for alleged violations by the defendants of the Securities Exchange Act of 1934, the Illinois Securities Act and various other statutes and common law in connection with the Barron Private Placement (see Note 4). The alleged violations were based upon, among other things, alleged intentional and negligent misrepresentations made by the Company in the Preferred Stock Purchase Agreement dated September 6, 2006 and alleged breaches of such agreement by the Company.
Prior to and subsequent to the filing of the complaint the Company is in negotiations with Barron for the repurchase by the Company of the securities sold to Barron. The Company believes it has an oral understanding with Barron to settle all of Barron’s claims by repurchasing all of the Preferred Stock and Warrants for $2 million in cash. The oral understanding is not binding and is subject to the execution of a definitive settlement agreement between Barron and the Company. As of January 17, 2008 the Company did not have a commitment from any person to finance the $2 million purchase price required to be paid under the proposed settlement agreement. No assurance can be provided that a definitive settlement will be entered into and consummated by the parties.
The Company may be involved in routine litigation incidental to the normal course of business. While it is not feasible to predict or determine the final outcome of these claims, the Company believes the resolution will not have a material adverse effect on its financial position, results of operations or liquidity.
NOTE 8 – Concentrations and Credit Risk
During the period from January 1, 2007 to September 30, 2007 revenues of two customers accounted for approximately $168,000 of gross revenue (representing approximately 42% and 10%, respectively, of gross revenue). At September 30, 2007 there were outstanding receivables of approximately $116,255 from one customer representing approximately 63% of gross accounts receivable.
During 2007, the Company’s sole product supplier was Biosafe.
NOTE 9 – Other
· | On March 17, 2007, the stockholders of the Company voted by unanimous written consent to remove Fred Fitzsimmons without cause (as permitted by the By-laws of the Company) as a director of the Company and elect Michael Carney to fill the vacancy on the Board of Directors thereby created. There are no arrangements or understandings between Mr. Carney and any other persons pursuant to which he was selected as a director of the Company. |
12
· | On March 28, 2007, the Board of Directors of the Company elected Ernest Azua as an Executive Vice President of the Company for an interim period until the selection of a new President and Chief Executive Officer of the Company. Mr. Azua was a Senior Vice President and Director of Intellectual Property Management with Biosafe Medical Technologies, Inc. Mr. Azua shall be paid a salary at the rate of $125,000 per year for his full-time services to the Company. |
· | On March 13, 2007 an involuntary bankruptcy petition was filed against Biosafe, the Company’s principal supplier, in the United States Bankruptcy Court for the Northern District of Illinois Eastern Division. On May 15, 2007, upon joint motion of the creditors who filed the involuntary petition and Biosafe, the petition was dismissed. |
· | On August 7, 2007, Henry Warner resigned as Chairman of the Board of Directors in order to devote more time to his other business interests. On such date, the directors of the Company elected Kurt Katz to replace Mr. Warner. Mr. Warner has agreed to remain as a director of the Company. |
13
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
The following discussion should be read in conjunction with the unaudited financial statements and accompanying notes included elsewhere in this Report.
This Item 2 contains forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Report. Actual results may differ materially from those included in such forward-looking statements. Factors which could cause actual results to differ materially include those set forth in our Annual Report on Form 10-KSB for the year ended December 31, 2006 ("2006 10-KSB") and under the heading "Forward Looking Statements" in this Item 2 of Part I of this Report.
Forward-Looking Statements
This quarterly report on Form 10-QSB contains "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements regarding the Company's expected financial position, business and financing plans are forward-looking statements. Such forward-looking statements are identified by use of forward-looking words such as "anticipates," "believes," "plans," "estimates," "expects," and "intends" or words or phrases of similar expression. These forward-looking statements are subject to various assumptions, risks and uncertainties, including but not limited to, changes in political and economic conditions, demand for the Company's products, acceptance of new products, technology developments affecting the Company's products and to those discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Accordingly, actual results could differ materially from those contemplated by the forward-looking statements
In addition to the other information set forth in this report, you should carefully consider the risk factors disclosed under part 1 - “Item 1. Description of Business - Risk Factors” in our 2006 10-KSB, which could materially adversely affect our business, financial condition, operating results and cash flows. The risks and uncertainties described in our 2006 10-KSB are not the only ones we face. Risks and uncertainties not currently known to us or that we currently deem immaterial also may materially adversely affect our business, financial condition operating results or cash flows. Since December 31, 2006, there have been no significant changes relating to risk factors.
Summary of Business
We (we also sometimes refer to ourselves herein as “Lab123” or the “Company”) are engaged in the marketing of clinical diagnostic products for use in disease detection and prevention. We were founded by Biosafe Laboratories, Inc. (“Biosafe”) to enable Biosafe to exploit certain of its technology by entering into a license agreement with us pertaining to 5 diagnostic products (the “Diagnostic Products”). Under the license agreement with Biosafe we sell Diagnostic Products to retail drug stores, retail drug mass merchandisers, and the distributors, marketers, brokers and group buyers who supply medical products to retail drug stores, retail drug mass merchandisers in the United States and to internet-based retail drug companies (the “Market”). Our products specialize in the use of micro-sample blood transportation devices and unique, scientific procedures for the clinical testing of these micro-blood samples. From time to time we may obtain terms from Biosafe, our sole supplier, that are beneficial to us that we may not normally obtain if we would seek the same terms from an outside vendor.
14
Plan of Operation
At September 30, 2007, the Company’s net cash available was approximately $45,672. The Company does not have any plans for significant capital expenditures or research and development projects and believes that its current operations will sustain its contractual obligations. The Company also does not have, nor does it plan to have, any significant debt or off balance commitments that could consume material amounts of cash during the next twelve months.
It is possible that the Company may need to hire or retain additional employees or consultants.
One of the Company’s current strategies is to concentrate on developing relationships with customers that offer the best combination of profitability and payment terms. Management believes that with this strategy and its relatively conservative plan for future general cash commitments, cash resources and cash flows for the next twelve months will be sufficient to adequately sustain operations.
We are dependent upon the continued financial support from our stockholder, Biosafe, to fund our operations and implement our business plan. In the event that we do not generate sufficient cash from operations to meet our operating requirements management expects that we will be able to obtain additional funds by either equity, debt financing and/or related party advances, although no assurance can be given that any such financing will be available on terms acceptable to us or at all.
While acquisitions may be considered during the next twelve months, the primary focus of the Company will be to develop or acquire new products that can be sold via a sales representative or contractual joint venture. A purchase of an additional product line in the next year is possible, but not likely.
During the first three quarters of 2007 the Company maintained contact with some large retailing organizations, to which we had provided samples of our test kits and started exploratory conversations late in 2006. We have filed the proper documents to become a supplier to two large retailing organization and we received from one such organization a purchase order for over $135,000 for Anemia Meters in August 2007 and shipped products late August and early September.
15
Results of Operations
The Company was formed on August 25, 2006, and, accordingly, we do not have results of operations comparisons with the third quarter or first nine months ended September 30, 2006. The Company’s net losses during the three and nine months ended September 30, 2007 were $47,969 and $400,177 respectively.
We do not know of any trends, events or uncertainties that have or are reasonably likely to have a material impact on the Company’s short-term or long-term liquidity, its net sales, revenues or income from continuing operations. The Company is still in the development stage. It is seeking venues to grow its business operations.
While management believes its plans for operations should enable the Company to generate sufficient cash flows to adequately sustain its operations, there is no certainty that these plans will succeed. In such event the Company may require additional working capital through bank borrowings or the issuance of debt or equity securities. There is no assurance that additional capital would be available to the Company on satisfactory terms or at all.
During the three months ended September 30, 2007, we had $200,296 in revenues with a gross margin of $90,121 that includes $25,000 of amortization of the license agreement for the three months ended September 30, 2007. For the nine month period we had revenues of $331,570 and a gross margin of $118,451. Since the Company’s inception we have incurred net losses of $522,479 and as of September 30, 2007 have working capital of $461,201 that we believe is sufficient to sustain our operations for the next several months. If necessary, we expect that we will be able to obtain additional funds by equity financing and/or related party advances; however, there is no assurance that additional funding will be available on satisfactory terms or at all to the extent required to address particular needs.
Liquidity and Capital Resources
Our territorial and intellectual license agreement for the retail marketing rights of five products from Biosafe Medical Technologies, Inc., required us to pay a $1,000,000 initial cash payment in 2006. This payment was the main cash outflow for us during 2006. The license agreement also grants us a non-exclusive, non-transferable and non-assignable intellectual property license to use Biosafe’s patents, trademarks and technology rights relating to the licensed products and the processing and reporting of laboratory analyses of samples collected using the products. Our only other large expenditure during the period ended December 31, 2006 was a 50% deposit for the purchase of 100,000 Anemia Meters from Biosafe Laboratories, Inc. for $300,000. During the three months ended March 31, 2007 we paid Biosafe an additional $75,000 deposit for a total of approximately $375,000 of inventory. As of September 30, 2007 the deposit balance was $287,844.
16
At September 30, 2007, the Company had available cash of approximately $45,672. In addition, the Company continues to suffer recurring losses from operations and has an accumulated deficit since inception of approximately $1,834,608. The accompanying financial statements have been prepared assuming that that the Company will continue as a going concern, which implies the Company will continue to meets its obligations and continue its operations for the next fiscal year. Realization values may be substantially different from carrying values as shown and these condensed financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company has a deficiency accumulated during the development stage of $1,834,608 and accumulated net losses of $522,479 since inception and may not have sufficient working capital to sustain its operations after the near term. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. Management's plans with respect to these matters include raising additional capital through future issuances of stock and/or equity and finding sufficient profitable markets for its products to generate sufficient cash to meet its business obligations. However, there can be no assurance that the Company will be able to obtain sufficient funds to continue the development of its product, marketing plan and distribution network.
In order to settle a lawsuit brought against the Company by Barron (see Note 7), the Company has a non-binding oral understanding with Barron to pay to Barron $2 million in cash to repurchase all of the securities of the Company held by Barron. As of January 17, 2008 the Company did not have a commitment from any person to provide the Company with financing sufficient to pay such purchase price and there can be no assurance that such financing will be obtained.
Contractual Obligations and Commitments
The Company has not incurred any material commitments for capital expenditures.
Critical Accounting Policies
Our condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States. These generally accepted accounting principles require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net revenues and expenses during the reporting period. Actual results could differ from those estimates. Our significant accounting policies are described in the notes to the consolidated financial statements included in our 2006 10-KSB. Judgments and estimates of uncertainties are required in applying our accounting policies in many areas. Management has discussed the development and selection of these policies with the Audit Committee of the Company’s Board of Directors, or its equivalent, and the Audit Committee of the Board of Directors, or its equivalent, has reviewed the Company’s disclosures of these policies. There have been no material changes to the critical accounting policies or estimates reported in the Management’s Discussion and Analysis section of the audited financial statements for the year ended December 31, 2006 as filed with the SEC.
17
Recently Adopted Pronouncements
We adopted the Financial Accounting Standards Board’s (“FASB”) Interpretation No. 48, “Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109 (“FIN 48”) effective January 1, 2007 and we also changed the method of accounting following the guidance of the FASB’s staff position provided in Emerging Issues Task Force (“EITF”) 00-19-2 (“FSP EITF 00-19-2”) as further described in Note 4 to our condensed financial statements.
The Company adopted Financial Accounting Standards Board's Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statement No. 109" ("FIN 48"), effective January 1, 2007. FIN 48 clarifies the accounting for uncertainty in income taxes recognized in financial statements and requires the impact of a tax position to be recognized in the financial statements if that position is more likely than not of being sustained by the taxing authority. FIN 48 is effective for fiscal years beginning after December 15, 2006, and is to be applied to all open tax years as of the date of effectiveness. FIN 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. There were no unrecognized tax benefits as of January 1, 2007.
The Company has identified its federal tax return and its state tax returns in Illinois as "major" tax jurisdictions, as defined. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The evaluation was performed for the 2006 tax year, which will be the only period subject to examination, since the Company was formed on August 25, 2006. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position. In addition, the Company did not record a cumulative effect adjustment related to the adoption of FIN 48.
The Company’s policy for recording interest and penalties associated with audits is to record such items as a component of income tax expense. No interest or penalties on income taxes have been recorded during the three months ended September 30, 2007. The Company does not expect its unrecognized tax benefit position to change during the next twelve months. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position. The adoption of the provisions of FIN 48 did not have a material impact on the Company’s financial position, results of operations and cash flows.
Recent Accounting Pronouncements
In September 2006, the FASB issued SFAS No. 157, "Accounting for Fair Value Measurements." SFAS No. 157 defines fair value, and establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosure about fair value measurements. SFAS No. 157 is effective for financial statements issued subsequent to November 15, 2007. The Company does not expect the new standard to have any material impact on the financial position, results of operations and cash flows.
18
In December 2006, the FASB issued FASB Staff Position (“FSP”) EITF 00-19-2 “Accounting for Registration Payment Arrangements” (“FSP EITF 00-19-2”) which specifies that the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement should be separately recognized and measured in accordance with SFAS No. 5, “Accounting for Contingencies.” Adoption of FSP EITF 00-19-02 is required for fiscal years beginning after December 15, 2006. The adoption of FSP EITF 00-19-02 did not have a material impact on the Company’s condensed financial position, results of operations or cash flows.
In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities" ("SFAS 159"). SFAS 159 provides companies with an option to report selected financial assets and liabilities at fair value. The objective of SFAS 159 is to reduce both complexity in accounting for financial instruments and the volatility in earnings caused by measuring related assets and liabilities differently. Generally accepted accounting principles have required different measurement attributes for different assets and liabilities that can create artificial volatility in earnings. The FASB has indicated it believes that SFAS 159 helps to mitigate this type of accounting-induced volatility by enabling companies to report related assets and liabilities at fair value, which would likely reduce the need for companies to comply with detailed rules for hedge accounting. SFAS 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. SFAS 159 does not eliminate disclosure requirements included in other accounting standards, including requirements for disclosures about fair value measurements included in SFAS 157 and SFAS No. 107, "Disclosures about Fair Value of Financial Instruments." SFAS 159 is effective for the Company as of the beginning of an entity’s first fiscal year that begins after November 15, 2007. The adoption of this pronouncement is not expected to have an impact on the Company's financial position, results of operations or cash flows.
Off Balance Sheet Arrangements
The Company is not party to nor has it any plans to become a party to any off balance sheet arrangements.
ITEM 3. CONTROLS AND PROCEDURES
The Company’s Executive Vice President, who is also the acting principal financial officer and principal executive officer, has evaluated the effectiveness of the Company’s “disclosure controls and procedures” as such term is defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-QSB. The evaluation process, including the inherent limitations on the effectiveness of such controls and procedures is more fully discussed below. Based upon his evaluation, the acting principal financial officer has concluded that the Company’s disclosure controls and procedures were not effective.
19
These controls were deemed not effective on account of a material weakness, which relates to limited segregation of duties and a lack of necessary corporate accounting resources. Management is aware that there is a lack of segregation of duties at the Company due to the sole employee dealing with general administrative and financial matters. Additionally, there is a lack of a chief financial officer in the accounting department to critically evaluate and implement accounting principles and at times transactions are recorded improperly and require additional procedures and adjustments to be made by our auditors. We have implemented certain procedures to help minimize the risks associated with this material weakness, including using the services of Biosafe Laboratories, Inc.’s accounting staff to act as an interim financial and accounting consultant to review and compile our financial statements on a quarterly and annual basis. When resources permit, we do intend to hire a chief financial officer with appropriate public company experience to relieve the sole employee of his current chief financial officer duties.
Except as described above, there were no significant changes in our internal controls over financial reporting that occurred during the quarter ended September 30, 2007 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On December 10, 2007 Barron Partners, L.P. (“Barron”) filed a Complaint in the United States District Court for the Southern District of New York against the Company, certain present and former directors and consultants to the Company and certain other persons, including Biosafe Laboratories, Inc. and Biosafe Medical Technologies, Inc., to recover unquantified damages against the defendants for alleged violations by the defendants of the Securities Exchange Act of 1934, the Illinois Securities Act and various other statutes and common law in connection with Barron’s purchase in September 2006 of Series A Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Preferred Stock”) and warrants to purchase common stock of the Company (the “Warrants”). The alleged violations were based upon, among other things, alleged intentional and negligent misrepresentations made by the Company in the Preferred Stock Purchase Agreement between the Company and Barron dated September 6, 2006 and alleged breaches of such agreement by the Company.
Prior to and subsequent to the filing of the complaint, we were in negotiations with Barron concerning a repurchase by us of the securities we sold to Barron. We believe that we have a non-binding oral understanding with Barron to settle all of Barron’s claims by repurchasing all of the Preferred Stock and Warrants for $2 million in cash. The agreement is subject to the execution of a definitive settlement agreement between Barron and us.
As of January 17, 2008 a summons regarding the action set forth in the complaint has not been served upon us. Counsel for Barron has agreed not to serve upon us any summons while settlement negotiations are proceeding.
As of January 17, 2008 the Company did not have a commitment from any person to finance the $2 million purchase price required to be paid under the proposed settlement agreement. No assurance can be provided that a definitive settlement will be entered into and consummated by the parties.
Except as set forth above, there are no material legal proceedings against us.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three and nine months ended September 30, 2007 we did not sell or issue any equity securities.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDER
None.
ITEM 5. OTHER INFORMATION
On August 7, 2007 Henry Warner resigned as Chairman of the Board of Directors in order to devote more time to his other business interests. On such date, the directors of the Company elected Kurt Katz to replace him as Chairman of the Board. Mr. Warner has agreed to remain as a director of the Company.
20
ITEM 6. EXHIBITS
31.1 | Certification of the Principal Executive Officer and Principal Financial Officer of Lab123, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. * |
32.1 | Certification of the Principal Executive Officer and Principal Financial Officer of Lab123, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. * |
* Filed herewith
21
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LAB123, INC.
By: Ernest Azua
Name: Ernest Azua
Title: Executive Vice President
(Principal Executive Officer and Principal
Financial and Accounting Officer)
Date: January 18, 2008
22